Viatris was classified into the Zacks Medical Services industry as of August 7, 2025.

1 report, 1 independent Updated Aug 7

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Mylan

Keep exploring

Part of

Viatris is involved in a development where Australia, New Zealand, and Japan are part of the JANZ segment. All 1 developments

The entities involved

Mylan
former pharmaceutical company
- Mylan and Zymeworks are involved in a deal aimed at bolstering Zymeworks’ commercial portfolio, related to COPD therapy.Mon 11:01
- Zymeworks is leveraging Irish tax attributes as part of its deal with Mylan.Mon 11:01

Coverage

Newest first; wire copies grouped

Aug 7ZacksViatris (VTRS) Tops Q2 Earnings and Revenue Estimates Viatris (VTRS) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to ear